Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CYP3A5,CYP3A5, encodes a member of the cytochrome P450 superfamily of enzymes. Additionally we are shipping CYP3A5 Kits (14) and CYP3A5 Proteins (3) and many more products for this protein.
Showing 10 out of 61 products:
Human Polyclonal CYP3A5 Primary Antibody for EIA, WB - ABIN453603
Murray, Pritchard, Melvin, Burke: Cytochrome P450 CYP3A5 in the human anterior pituitary gland. in FEBS letters 1995
CYP3A5 genetic variation is associated with kidney dysfunction and poor response to everolimus maintenance.
Both donor and recipient CYP3A5 genotype significantly influences tacrolimus once daily pharmacokinetics in stable liver transplant recipients, while CYP3A4 (show CYP3A4 Antibodies)*22 is not a suitable biomarker
findings suggest that the presence of the CYP3A5*1 allele contributes to marked elevation of CYP3A activity associated with recovery of renal function after kidney transplantation
CYP3A5 genetic polymorphisms may influence outcome of taxane therapy in Roma and Hungarian populations.
Early postpartum women possessed higher CYP3A activity based on plasma 4beta-hydroxycholesterol and had a large pharmacokinetic variability in amlodipine disposition.
The polymorphism of ABCB1 (show ABCB1 Antibodies) (C3435T) has an important role in the manifestation of toxicities and drug exposure, but not polymorphism of CYP3A5.
a critical role of the CYP3A5 6986A>G and CYP3A4 (show CYP3A4 Antibodies) -392A>G polymorphisms on the variation of Tac (show IL2RA Antibodies) exposure during the early and the late post-transplant phase, respectively.
rs776746 and rs15524 in the CYP3A5 gene tend to affect carbamazepine metabolism in patients with epilepsy.
CYP3A5 genotyping and dose adjustments of tacrolimus should be performed to prevent acute renal dysfunction in lupus nephritis patients taking tacrolimus once daily
CYP3A5*1 in either the donor or recipient resulted in higher mean daily doses of tacrolimus or its modified formulation to achieve target drug exposure in liver transplant patients.
This gene,CYP3A5, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by glucocorticoids and some pharmacological agents. The enzyme metabolizes drugs such as nifedipine and cyclosporine as well as the steroid hormones testosterone, progesterone and androstenedione. This gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1. This cluster includes a pseudogene, CYP3A5P1, which is very similar to CYP3A5. This similarity has caused some difficulty in determining whether cloned sequences represent the gene or the pseudogene. Multiple alternatively spliced transcript variants have been identified for this gene.
cytochrome P450 3A5
, aryl hydrocarbon hydroxylase
, cytochrome P450 HLp2
, cytochrome P450, subfamily IIIA (niphedipine oxidase), polypeptide 5
, cytochrome P450-PCN3
, flavoprotein-linked monooxygenase
, microsomal monooxygenase
, xenobiotic monooxygenase